Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.

Details

Ressource 1Download: 28509765_BIB_15F2678EE65F.pdf (470.85 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_15F2678EE65F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Journal
Melanoma research
Author(s)
Mangana J., Cheng P.F., Kaufmann C., Amann V.C., Frauchiger A.L., Stögner V., Held U., von Moos R., Michielin O., Braun R.P., Levesque M.P., Goldinger S.M., Dummer R.
ISSN
1473-5636 (Electronic)
ISSN-L
0960-8931
Publication state
Published
Issued date
08/2017
Peer-reviewed
Oui
Volume
27
Number
4
Pages
358-368
Language
english
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Abstract
Metastatic melanoma is a highly aggressive disease. Recent progress in immunotherapy (IT) and targeted therapy (TT) has led to significant improvements in response and survival rates in metastatic melanoma patients. The current project aims to determine the benefit of the introduction of these new therapies in advanced melanoma across several regions of Switzerland. This is a retrospective multicenter analysis of 395 advanced melanoma patients treated with standard chemotherapy, checkpoint inhibitors, and kinase inhibitors from January 2008 until December 2014. The 1-year survival was 69% (n=121) in patients treated with checkpoint inhibitors (IT), 50% in patients treated with TTs (n=113), 85% in the IT+TT group (n=66), and 38% in patients treated with standard chemotherapy (n=95). The median overall survival (mOS) from first systemic treatment in the entire study cohort was 16.9 months. mOS of patients treated either with checkpoint or kinase inhibitors (n=300, 14.6 months) between 2008 and 2014 was significantly improved (P<0.0001) compared with patients treated with standard chemotherapy in 2008-2009 (n=95, 7.4 months). mOS of 61 patients with brain metastases at stage IV was 8.1 versus 12.5 months for patients without at stage IV (n=334), therefore being significantly different (P=0.00065). Furthermore, a significant reduction in hospitalization duration compared with chemotherapy was noted. Treatment with checkpoint and kinase inhibitors beyond clinical trials significantly improves the mOS in real life and the results are consistent with published prospective trial data.

Keywords
Antibodies, Monoclonal/therapeutic use, Cohort Studies, Humans, Immunotherapy/methods, Melanoma/drug therapy, Melanoma/pathology, Middle Aged, Retrospective Studies, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Switzerland
Pubmed
Web of science
Create date
23/05/2017 17:23
Last modification date
20/08/2019 13:45
Usage data